Overall, these data suggest that primitive quiescent CML stem cells (with or without ABL-K mutations) are protected from targeted therapies under the influence of cell-autonomous pathways or external cues such as niche-driven mechanisms, leading to the accumulation of a genuine leukemic reservoir. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.